Outlook's Vision Drug Enters High-Stakes FDA Dispute Resolution

ISELIN, NJ – April 07, 2026 – In a critical escalation of its lengthy regulatory battle, Outlook Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has accepted its Formal Dispute Resolution Request (FDRR) for ONS-5010/LYTENAVA™. The biopharmaceutical company is seeking approval for its ophthalmic formulation of bevacizumab to treat neovascular (wet) age-related macular degeneration (AMD), a leading cause of vision loss in older adults.

The FDA has granted a meeting with a deciding official, scheduled for this month, which represents a pivotal opportunity for the company to appeal a decision that has so far blocked its entry into the lucrative U.S. market. This move follows a third Complete Response Letter (CRL) issued by the agency in December 2025, which once again denied approval for the much-anticipated drug.

“We look forward to our discussions with the FDA and remain committed to our position that data on safety and efficacy for LYTENAVA demonstrated in NORSE TWO and NORSE EIGHT provide sufficient evidence to support approval and bring a much-needed FDA approved option for patients,” said Bob Jahr, Chief Executive Officer of Outlook Therapeutics, in a statement.

The Regulatory Gauntlet

Outlook's journey with the FDA has been a case study in regulatory persistence. The company's pursuit of a Biologics License Application (BLA) for ONS-5010 has been met with a series of setbacks. The first CRL in August 2023 cited issues with manufacturing and controls. After addressing those, a second CRL in August 2025 and the most recent one in December 2025 both pointed to a perceived lack of substantial evidence of effectiveness.

The core of the dispute lies in the FDA's interpretation of the clinical data. While the agency acknowledged that the company's NORSE TWO Phase 3 trial was an adequate and well-controlled study that met its primary endpoints, it has consistently requested additional confirmatory evidence. The company's resubmission included data from its NORSE EIGHT trial, which did not meet its primary goal, a factor that likely contributed to the FDA's decision. Throughout this process, the FDA has not raised any safety concerns with the drug.

Frustrated by the impasse at the review division level, Outlook has invoked the FDRR process. This formal mechanism is reserved for resolving scientific and medical disputes that cannot be settled through standard interactions. By escalating the issue, the company will present its case to a higher-level official within the FDA's Center for Biologics Evaluation and Research (CBER), who has the authority to overrule the initial decision. The outcome of this April meeting could either finally pave a path to U.S. approval or force the company into costly and time-consuming new clinical trials.

Standardizing a Workhorse Treatment

The regulatory struggle belies the potential clinical impact of ONS-5010. If approved, it would be the first and only FDA-sanctioned ophthalmic formulation of bevacizumab for retinal diseases. Bevacizumab, marketed for cancer treatment as Avastin, is already a cornerstone of wet AMD therapy in the United States, but its use is entirely off-label.

Currently, ophthalmologists rely on compounding pharmacies to repackage Avastin from large vials intended for intravenous cancer therapy into tiny syringes suitable for injection into the eye. While this practice has made wet AMD treatment more affordable, it carries inherent risks. The repackaging process is not overseen by the FDA, leading to concerns about inconsistent dosing, potential contamination, and a lack of standardized safety monitoring.

ONS-5010/LYTENAVA™ was developed specifically to solve this problem. It offers a sterile, ophthalmic-grade bevacizumab produced in a controlled environment, supported by a fully domestic U.S. manufacturing supply chain, and accompanied by FDA-approved labeling and pharmacovigilance. For physicians and patients, this would represent a significant leap forward in safety, consistency, and quality assurance for one of the most commonly used drugs in ophthalmology.

A Tale of Two Continents

The company's frustrating experience in the U.S. stands in stark contrast to its success across the Atlantic. LYTENAVA™ has already secured Marketing Authorization from both the European Commission and the UK's Medicines and Healthcare products Regulatory Agency (MHRA). Commercial launches began in Germany, Austria, and the UK in mid-2025, targeting a European market where an estimated 2.8 million off-label bevacizumab injections are administered annually.

This divergence highlights the differing philosophies and risk-benefit assessments between major global regulators. While European authorities were satisfied with the totality of the clinical evidence, the FDA has maintained a higher bar for what it considers sufficient confirmatory data. This transatlantic split creates significant challenges for biopharmaceutical companies and underscores the complexities of navigating a fragmented global drug development landscape.

The European approval and commercial rollout, however, provide crucial validation for Outlook. It demonstrates that other respected regulatory bodies have deemed the drug safe and effective, a point the company will surely emphasize in its discussions with the FDA's deciding official.

Wall Street's High-Stakes Wager

For investors, Outlook Therapeutics (Nasdaq: OTLK) has been a volatile and high-risk proposition. The company's stock price has plummeted over the past year, battered by the successive FDA rejections. The current share price reflects deep market uncertainty about the drug's future in the United States.

Despite the risk, some on Wall Street remain optimistic. The consensus rating among a trio of analysts covering the stock is a 'Buy', with price targets suggesting a potential upside of over 1,000% if U.S. approval is secured. Analysts point to the European revenue stream, which is projected to grow significantly, as a key driver that validates the product's market potential. The news of the FDA accepting the FDRR provided a small but immediate boost to the stock, signaling that investors see the upcoming meeting as a credible, albeit long-shot, path to victory.

With the FDRR meeting now on the calendar, Outlook Therapeutics and its investors are at a critical inflection point. The company has one more chance to make its case directly to FDA leadership. The outcome will not only determine the fate of ONS-5010 in the world's largest pharmaceutical market but will also serve as a defining moment for a company that has staked its entire future on standardizing a vital treatment for millions at risk of losing their sight.